Obesity Drug Developer Metsera Files for $100M IPO

Seeking Alpha06:54

Dividend Aristocrats Can't Handle Rising Rates. These Are Better Income Bets. -- Barrons.com

Barron's03:15

Goldman Sachs Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Announces Target Price $124

Futu NewsJan 13 23:33 · Ratings

The world's first oral GLP-1 receptor agonist, Novo-Nordisk A/S, has been fully launched in China.

On January 11, Gelonghui reported that Novo-Nordisk A/S announced the comprehensive launch of its Innovative Drug, Ozempic (semaglutide tablets), in China today. As the first oral GLP-1RA, Ozempic combines SNAC technology to achieve significant benefits such as lowering blood sugar, weight loss, blood pressure reduction, and lipid regulation. The once-daily oral administration will improve patient adherence, creating a new era in the treatment of type 2 diabetes, helping achieve quality blood sugar targets and comprehensive metabolic management, bringing new hope to 0.14 billion diabetes patients in China.

Gelonghui FinanceJan 11 18:10

Express News | Novo-Nordisk A/S is confident in the economic prospects of China and its development in the country, and is willing to continue investing in the Chinese market.

BreakingsJan 11 09:41

European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading

MT NewswiresJan 11 00:17